| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Karyopharm Therapeutics (NASDAQ:KPTI) through any online brokerage.
Other companies in Karyopharm Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Karyopharm Therapeutics has a consensus price target of $32.00.
The stock price for Karyopharm Therapeutics (NASDAQ: KPTI) is $0.5769 last updated October 9, 2026 at 1:40 PM EDT.
There are no upcoming dividends for Karyopharm Therapeutics.
Karyopharm Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Karyopharm Therapeutics.
Karyopharm Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
